Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2THBX)

Drug Name

OM-174 Drug Info

Synonyms

UNII-HC3530GGGG; HC3530GGGG; Defoslimod [INN]; OM 174 lipid; 2-Deoxy-6-o-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate.; 2-Deoxy-6-O-(2-deoxy-2-((R)-3-hydroxytetradecanamido)-beta-D-glucopyranosyl)-2-((R)-3-hydroxytetradecanamido)-alpha-D-glucopyranose 1,6'-bis(dihydrogen phosphate) 2'(3)-laurate

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 9833422
CAS Number: CAS 171092-39-0
TTD Drug ID: DM2THBX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[3]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[4]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[5]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[6]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[8]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[8]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[9]
LZ-8	DM679IY	Autoimmune diabetes	5A10	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Toll-like receptor 2 (TLR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[4]
MCS-18	DMX4U0B	Autoimmune diabetes	5A10	Phase 2	[10]
OPN-305	DM1IBRT	Myelodysplastic syndrome	2A37	Phase 2	[11]
MALP-2S	DMBZ68C	Pancreatic cancer	2C10	Phase 1/2	[12]
Lipoteichoic acid	DMEMRW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[14]
S-(Dimethylarsenic)Cysteine	DMSCHL0	Discovery agent	N.A.	Investigative	[15]
CBLB-612	DMCFR8U	Radiation syndrome	NF00	Investigative	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 2 (TLR2)	TTY7ZHS	TLR2_HUMAN	Modulator	[2]
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01800812) Effects of OM-174 in Adult Patients With Solid Tumors. U.S. National Institutes of Health.
2	Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
3	Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
4	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
5	Clinical pipeline report, company report or official report of Takeda (2009).
6	Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
9	Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
10	The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
11	Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
12	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
13	Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
14	Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
15	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752).